Endovastec(SH:688016) Sou Hu Cai Jing·2025-09-09 19:48Summary of Key Points Core Viewpoint - The company, Xinmai Medical, reported a decline in both revenue and net profit for the first half of 2025, attributed to adjustments in product pricing and marketing strategies [1][2]. Trading Information - As of September 9, 2025, Xinmai Medical's stock closed at 110.5 yuan, down 2.32%, with a turnover rate of 1.63% and a trading volume of 20,100 shares, amounting to a total transaction value of 224 million yuan [1]. Fund Flow - On September 9, the main funds experienced a net outflow of 7.86 million yuan, accounting for 3.51% of the total transaction value. Retail investors saw a net inflow of 8.39 million yuan, representing 3.75% of the total transaction value [1][2]. Company Announcements - Xinmai Medical's revenue for the first half of 2025 was 714 million yuan, reflecting a year-on-year decrease of 9.24%. The net profit attributable to shareholders was 315 million yuan, down 22.03% year-on-year, primarily due to changes in product pricing and promotional strategies [1][2]. - The company invested a total of 63.25 million yuan in research and development, which is 8.85% of its revenue. The company faces risks related to new product development, technology iteration, talent retention, market competition, and centralized procurement policies [1]. - The use of raised funds is compliant, with the controlling shareholder holding 40.31% of the shares, and there are no pledges, freezes, or reductions in holdings reported [1].